MedTrace Logo

Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:

NCT00356018 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2020-03-04

No results posted yet for this study

Summary

To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.

Conditions

Interventions

BEHAVIORAL

Compliance

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Orlando Health, Inc.

    lead OTHER

Principal Investigators

  • Jane Boggs, MD · Physician

Eligibility

Min Age
16 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-07-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00356018 on ClinicalTrials.gov